IFNGR2 and non-small cell lung carcinoma: In patients with stage III NSCLC, we identified complement receptor type 2 (CR2) and interferon gamma receptor 2 (IFNGR2) as potential prognostic proteins (CR2–HR: 0.00, 95% CI: 0.00–0.12; IFNGR2–HR: 0.04, 95% CI: 0.00–0.46) (Figure 4d).